MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 205851 | Name: LGK974
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LGK974, also known as WNT974, is a selective and orally bioavailable porcupine (PORCN) inhibitor under development for the treatment of cancers that are driven by the Wnt pathway in a Wnt ligand-dependent manner. WNT974 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.

Chemical Structure

LGK974
LGK974
CAS#1243244-14-5 (free base)

Theoretical Analysis

MedKoo Cat#: 205851

Name: LGK974

CAS#: 1243244-14-5 (free base)

Chemical Formula: C23H20N6O

Exact Mass: 396.1699

Molecular Weight: 396.44

Elemental Analysis: C, 69.68; H, 5.08; N, 21.20; O, 4.04

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,950.00 Ready to ship
1g USD 3,950.00 Ready to ship
2g USD 6,850.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
2375595-49-4 (2HCl) 1243244-14-5 (free base)
Synonym
LGK974; LGK-974; LGK 974; WNT974; WNT 974; WNT-974
IUPAC/Chemical Name
2-(2',3-dimethyl-[2,4'-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide
InChi Key
XXYGTCZJJLTAGH-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H20N6O/c1-15-9-17(12-28-23(15)18-5-6-25-16(2)10-18)11-22(30)29-21-4-3-19(13-27-21)20-14-24-7-8-26-20/h3-10,12-14H,11H2,1-2H3,(H,27,29,30)
SMILES Code
O=C(NC1=NC=C(C2=NC=CN=C2)C=C1)CC3=CN=C(C4=CC(C)=NC=C4)C(C)=C3
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Biological target:
LGK-974 (NVP-LGK974, WNT974) is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM in TM3 cells.
In vitro activity:
Medicinal chemistry optimization of GNF-1331 was carried out to improve potency and pharmacokinetic properties. This effort led to the discovery of LGK974 (Fig. 1B), a highly specific and potent PORCN inhibitor. LGK974 effectively displaced [3H]-GNF-1331 with an IC50 of 1 nM in the PORCN radioligand binding assay (Fig. 1C and Fig. S1B). LGK974 also potently inhibited Wnt signaling in the aforementioned Wnt coculture assay with an IC50 of 0.4 nM (Fig. 1D). This inhibitory effect was rescued by the addition of exogenous Wnt3A CM (Fig. 1E). Additionally, LGK974 showed no major cytotoxicity in cells up to 20 µM (Fig. S1C). To further confirm the activity of LGK974 in blocking PORCN-dependent Wnt secretion, 293A cells were transfected with HA-tagged Wnt3A and treated with various doses of LGK974. As shown in Fig. 1F and Fig. S1D, LGK974 potently decreased levels of HA-Wnt3A in the supernatant with slightly increased levels of HA-Wnt3A in the cell lysate, suggesting that Wnt3A secretion was substantially inhibited by LGK974 in a dose-dependent manner. In Wnt-responsive cells, secreted Wnts cause phosphorylation of the Wnt coreceptor LRP6. In L-Wnt3A cells, a mouse cell line overexpressing Wnt3A, LGK974, strongly blocked Wnt-dependent phosphorylation of LRP6 (Fig. S1E). Reference: Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24277854/
In vivo activity:
In a murine MMTV-Wnt1 tumor model using s.c. implanted tumor fragments derived from MMTV-Wnt1 transgenic mice, LGK974 exhibited strong dose-dependent efficacy when administered daily (Fig. 2A). Briefly, changes in tumor volume for each of the treated (T) and control (C) groups were measured and used to calculate growth delay as expressed by the T/C ratio. A dose of 0.3 mg/kg LGK974 led to tumor growth delay (T/C: 26%), whereas a dose of 1 or 3 mg/kg induced very significant tumor regression (T/C: −47% or −63%, respectively) on day 13 of treatment. As shown in Fig. S2A, the regimen was well-tolerated without significant body weight loss in the mice. Similar efficacy was observed with LGK974 in a murine MMTV-Wnt3 model (Fig. S2B). Reference: Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24277854/
Solvent mg/mL mM
Solubility
DMSO 32.0 80.72
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 396.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, Harris JL. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25. PMID: 24277854; PMCID: PMC3864356. 2. Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, Charlat O, Xie Y, Porter JA, Pan S, Liu J, McLaughlin ME, Cong F. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54. doi: 10.1073/pnas.1307218110. Epub 2013 Jul 11. PMID: 23847203; PMCID: PMC3732970.
In vivo protocol:
1. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, Harris JL. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25. PMID: 24277854; PMCID: PMC3864356. 2. Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, Charlat O, Xie Y, Porter JA, Pan S, Liu J, McLaughlin ME, Cong F. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54. doi: 10.1073/pnas.1307218110. Epub 2013 Jul 11. PMID: 23847203; PMCID: PMC3732970.
1: Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, Harris JL. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25. PubMed PMID: 24277854; PubMed Central PMCID: PMC3864356. 2: Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, Charlat O, Xie Y, Porter JA, Pan S, Liu J, McLaughlin ME, Cong F. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54. doi: 10.1073/pnas.1307218110. Epub 2013 Jul 11. PubMed PMID: 23847203; PubMed Central PMCID: PMC3732970.